ERBB2 and invasive breast carcinoma: According to current guidelines of the College of American Pathologists for HER2 testing in breast cancer [2], Human Epidermal growth factor Receptor 2 (HER2) quantification must be routinely tested, in invasive breast cancer, recurrences, and metastases.